September 13, 2018 – It is with great pleasure we, Dementia 2018 would like to express by personal gratitude to invite you to the “12th World Congress on Dementia and Alzheimer Rehabilitation” scheduled during November 27-29, 2018 at Athens, Greece.

Dementia Meetings 2018 anticipates more than 500 participants around the globe to experience thought provoking Keynote lectures, oral, video & poster presentations. This year Dementia conference will offer ample opportunities for all stakeholders working on Dementia and Alzheimer and its rehabilitation to expose their research work.

Within this splendid setting, we plan to deliver a conference that will exceed your expectations. Our Dementia conference aims to make people with dementia feel safe and to create a familiar environment for them.

This year in Dementia 2018 conference, we hope that you will seize the opportunity to rekindle on-going connections and spark new ones with your colleagues from around the globe.

The Conference will be organized around the theme “Innovative Approaches to Support: Dementia & Alzheimer Rehabilitation”.


Track 1: Dementia
Dementia is not a specific disease. It's an overall term that describes a wide range of symptoms associated with a decline in memory or other thinking skills severe enough to reduce a person's ability to perform everyday activities. Alzheimer’s disease, vascular dementia, which occurs after a stroke, is the second most common dementia type.
Track 1-1Dementia with Lewy Bodies
Track 1-2mixed dementia
Track 1-3Front temporal dementia
Track 1-4Normal pressure hydrocephalus
Track 1-5Signs and symptoms of dementia
Track 1-6Risk factors of cognitive decline

Track 2: Alzheimer’s Disease
Alzheimer's is the most common form of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60 to 80% of dementia cases. Alzheimer's is the most common form of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for 60 to 80% of dementia cases. Alzheimer's is not a normal part of aging.
Track2-1Risk Factors of Alzheimer’s
Track2-2Diagnosis of Alzheimer’s
Track2-3Treatments of Alzheimer’s
Track2-4Clinical Studies of Alzheimer’s
Track2-5Alzheimer’s disease Psychopathology and Disease Mechanisms

Track 3: Dementia and Aging
Aging: Not being able to remember details of a conversation or event that took place a year ago, Not being able to remember the name of an acquaintance, Forgetting things and events occasionally, Occasionally have difficulty finding words, You are worried about your memory but your relatives are not..

Dementia: Not being able to recall details of recent events or conversations, Not recognizing or knowing the names of family members, Forgetting things or events more frequently, Frequent pauses and substitutions when finding words, Your relatives are worried about your memory, but you are not aware of any problems.
Track 3-1Neuro-anatomical changes in ageing
Track 3-2Granulovacuolar degeneration
Track 3-3Advances of research in ageing and dementia

Track 4: Vascular Dementia
Vascular dementia occurs when vessels that supply blood to the brain become blocked or narrowed. Strokes take place when the supply of blood carrying oxygen to the brain is suddenly cut off. However, not all people with stroke will develop vascular dementia.
Track 4-1vascular dementia prognosis
Track 4-2Young onset dementia
Track 4-3Multi-infarct dementia
Track 4-4mixed dementia
Track 4-5Parkinson dementias
Track 4-6Advances in vascular dementia therapy

Track 5: Geriatrics Dementia and Cognitive Disorders
Geriatrics or geriatric medication may be a specialty that focuses on health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. There’s no set age at that patients are also underneath the care of a specialist or geriatric.
Track 5-1Delirium
Track 5-2Mild and Major Neurocognitive Disorder
Track 5-3cognitive impairment

Track 6: Animal Models in Dementia
The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation. Dementia is a clinical syndrome with abnormal degree of memory loss and impaired ability to recall events from the past often characterized by Alzheimer's disease.
Track 6-1Neurobehavioral Toxicology Testing
Track 6-2Pre-clinical testing and clinical translation
Track 6-3Protein-protein interactions
Track 6-4Genetics of translational models
Track 6-5Animal models of human cognitive aging

Track 7: Amyloid Protein in Alzheimer’s and Dementia
Alzheimer's disease (AD), the leading cause of dementia worldwide, is characterized by the accumulation of the β-amyloid peptide (Aβ) within the brain along with hyper phosphorylated and cleaved forms of the microtubule-associated protein tau.
Track 7-1Amyloid Imaging
Track 7-2FDG-PET
Track 7-3Amyloid Immunotherapy

Track 8: Amyloid Imaging in Dementia
The AIT(Amyloid Imaging Task Force) concluded that amyloid imaging could potentially be helpful in the diagnosis of people with cognitive impairment when considered along with other clinical information, and when performed according to standardized protocols by trained staff.

Track 9: Neurodegenerative Diseases
Degenerative nerve diseases affect many of your body's activities, such as balance, movement, talking, breathing, and heart function. Sometimes the cause is a medical condition such as alcoholism, a tumour, or a stroke. Other causes may include toxins, chemicals, and viruses. Sometimes the cause is not known.
Track 9-1Brain diseases
Track 9-2Traumatic brain injury
Track 9-3Amyotrophic lateral sclerosis
Track 9-4Spinal muscular atrophy
Track 9-5Migraine
Track 9-6Stroke

Track 10: Parkinson’s disease with Dementia
Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role. Parkinson’s disease usually begins around age 60, but it can start earlier. It is more common in men than in women.
Track 10-1Huntington’s Disease
Track 10-2Anxiety
Track 10-3Muffled speech

Track 11: Dementia Care Management
The developing number of vascular dementia patients prompts both approach, monetary and wellbeing association imperatives. Numerous social insurance frameworks have created case administration programs with a specific end goal to advance dementia patients and guardians care and administrations conveyance.
Track 11-1Advances in dementia care management
Track 11-2Dementia care management program
Track 11-3Undernutrition and obesity in dementia
Track 11-4Advance care planning

Track 12: Dementia Nursing
People with vascular dementia have different mental element shortfalls that incorporate every memory hindrance, that influences the adaptability to discover new data or review data already learned, and one or extra of the ensuing side effects apraxia, agonise, or official brokenness to such an extent that the mental element shortages adversely affect social or action working with a major decrease in past abilities.
Track 12-1Dementia nursing care plan
Track 12-2Music therapy in dementia
Track 12-3Physiotherapy for dementia
Track 12-4Clinical features of dementia
Track 12-5Therapeutic interventions in dementia

Track 13: Neuropharmacology
Neuropharmacology is an extremely wide locale of science that includes numerous parts of the sensory system from single neuron control to whole ranges of the cerebrum, spinal line, and fringe nerves. To better comprehend the premise behind medication advancement, one should first see how neurons speak with each other.
Track 13-1Neuroscience and neuropharmacology
Track 13-2Neurochemical interaction
Track 13-3Molecular neuropharmacology
Track 13-4Behavioral neuropharmacology
Track 13-5Advance research in neuropharmacology

Track 14: Recent Advancement in Treatments of Dementia
Currently, there is no cure for Alzheimer's. But drug and non-drug treatments may help with both cognitive and behavioural symptoms. Researchers are looking for new treatments to alter the course of the disease and improve the quality of life for people with dementia.
Track 14-1Medications for Memory Loss
Track 14-2Amyloid Immunotherapy
Track 14-3Clinical Trials

Track 15: Treating Dementia
Early discovery and exact analysis are critical, as vascular dementia is at any rate halfway preventable .Ischemic changes in the cerebrum are irreversible, however the patient with vascular dementia can exhibit times of solidness or even gentle change. Since stroke is a basic piece of vascular dementia, the objective is to forestall new strokes. This is endeavoured through decrease of stroke chance components, for example, hypertension, high blood lipid levels, atrial fibrillation, or diabetes mellitus.
Track 15-1Primary mental health care and nursing
Track 15-22Psychopharmacological treatment
Track 15-3Advanced drugs for dementia
Track 15-4Cognitive behavioural therapy
Track 15-5Family therapy in nursing

Track 16: Dementia Rehabilitation and Therapy
Novel therapeutics is a standout amongst the most energizing uses of data preparing frameworks is in diagnostics and treatment. This is not astonishing, given that illness analysis is in its center a data handling undertaking that finishes with a choice. In numerous infections, the conclusion can be performed in singular cells.
We are used to thinking of rehabilitation in terms of physical rehabilitation following injury, but it is equally relevant for people with cognitive, rather than physical, impairments. This includes people whose impairments result from long-term, progressive neurodegenerative conditions. In cognitive rehabilitation, these principles are applied to enable people with dementia to maintain or optimize functioning.
Track 16-1Novel therapeutics strategies for dementia
Track 16-2Novel therapeutics molecule
Track 16-3Anti-dementia drugs
Track 16-4Novel drug target for the treatment of dementia

Why to attend?
12th World Congress on Dementia and Rehabilitation is organizing an outstanding Scientific Exhibition/Program and anticipates the world's leading Neurologists, health professionals involved in the profession and practice of neuroscience. The event will also reflect interest of specialists in the clinical research on dementia and Alzheimer’s disease. Conference series organizing this international event for people to take part and gain a better understanding of such diseases, to access treatment as well as information, advice and support and to have their health monitored more closely.
This International meeting is an effort to make possible interactions among world leading scientists, research scholars, professionals, young researchers from different parts of the world to exchange their knowledge and conduct symposia, show experiments with new innovative techniques that disseminate information about clinical tradition, best practices, skills and knowledge in the field of neuroscience. In Dementia and Rehabilitation 2018, international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.

Target Audience:
Neurologists and Directors
Health care professionals
Industrial Experts
Nutritional Scientists
Lecturers and Students from Academia in the study of Dementia
Students from Academia in the research of Neurology
Neuro Physiotherapists

Access to all Sessions
Handbook & Conference Kit
CPD Certification
Abstracts will be published with DOI number
Certificate Accreditation by the International Organizing Committee
Abstracts will be published in the conference souvenir and respective international journals
Ask the Expert Forums (One to One Pre-Scheduled meeting on interest and availability)
Access to the attendees' email list (post conference)
25% abatement on the registration fees for the next annual conference
Coffee break (Refreshments and snacks) Lunch during the conference
Free Wi-Fi

Learning Objectives

1.Share and describe new developments in the field of Forensic Psychology & Criminology
2.They can compare research guidelines and good practices with new current practices and strength or gaps
3.Discover new research techniques in development with practical implication used in recovery treatment or research fields
4.Participants can build their networks of professionals and can find valuable resources
5.Explain recent or upcoming changes in policy to identify provider involvement areas
6.Demonstrate the knowledge while treating patients with psychological disorders in clinical aspects
7.Usage of various patient screening tools that used to identify usage of substance abuse and interpretation results
8.Enhance patient’s readiness to change in their risky behaviors by using motivational interviewing
9.Also, will be offer referral in regards to behavioral interventions which include support groups as well as mutual groups that will assist in recovery process

Participation Benefits:

Welcome Ceremony
Keynote Presentation
Presentation over concurrent streams
Half day Workshop
Poster Presentation
Video/ Virtual Presentation
Exhibitor and Sponsor displays
Symposium and Networking
Best Poster Award
Young Researcher Award

Why Athens

Athens is the capital of Greece. It was also known as the heart of Ancient Greece, It has a powerful civilization and empire. The city is still dominated by 5th-century BC landmarks, including the Acropolis, a hilltop citadel topped with ancient buildings like the colonnaded Parthenon temple. The Acropolis Museum, along with the National Archaeological Museum, preserves sculptures, vases, jewellery and more from Ancient Greece.


Athens has been a destination for travellers since antiquity. Over the past decade, the city's infrastructure and social amenities have improved, in part because of its successful bid to stage the 2004 Olympic Games. The Greek Government, aided by the EU, has funded major infrastructure projects such as the state-of-the-art Eleftherios Venizelos International Airport, the expansion of the Athens Metro system, and the new Attica Odes Motorway.
Athens was voted as the third best European city to visit in 2015 by European Best Destination. More than 240,000 people voted.

International SUPPORTED Journals:

1.Journal of Alzheimer’s Disease & Parkinsonism
2.Journal of Neurological Disorders
3.Brain Disorders & Therapy


Powered by WPeMatico